For the first time, the U.S.
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
The US Food and Drug Administration (FDA) has given IND approval for a Phase 2b study of a synthetic formulation of 5-MeO-DMT – BPL-003.
Reset Mind Sciences, a wholly-owned subsidiary of Little Green Pharma, has received Human Research Ethics Committee (HREC) approval for a trial investigating psilocybin-assisted psychotherapy for the...
Optimi Health has submitted an application to carry out a Phase I clinical trial investigating the safety of the combinatory use of psilocybin and MDMA in...
In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
Cybin’s CYB004-E Phase 1 trial evaluating DMT has completed dosing for four out of five participant cohorts.
Beckley Psytech has dosed the first participant in its Phase 1 single-ascending dose (SAD) study of ELE-101 – a novel intravenous formulation of psilocin – with...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
